High-Sensitivity C-Reactive Protein (hs-CRP): Inflammation, Cardiovascular Risk & Longevity

1. What Is C-Reactive Protein?

C-reactive protein (CRP) is an acute-phase reactant synthesized primarily by hepatocytes in response to interleukin-6 (IL-6) stimulation. It belongs to the pentraxin family of proteins and functions as a pattern recognition molecule, binding to phosphocholine on damaged cells and microbial surfaces¹.

The high-sensitivity CRP (hs-CRP) assay can detect CRP levels as low as 0.1 mg/L, enabling assessment of low-grade chronic inflammation — the type most relevant to aging and cardiovascular disease².

2. hs-CRP and the "Inflammaging" Hypothesis

Chronic low-grade inflammation — termed "inflammaging" by Franceschi et al. — is now recognized as one of the hallmarks of aging³. Unlike acute inflammation, which is protective and self-limiting, inflammaging involves persistent elevation of pro-inflammatory cytokines (IL-6, TNF-α, IL-1β) and acute-phase reactants including CRP.

Meta-analyses have established that elevated hs-CRP predicts:

• Cardiovascular disease events (HR 1.6-2.0 for highest vs lowest quartile)⁴
• All-cause mortality (HR 1.5-2.3)⁵
• Type 2 diabetes incidence (RR 1.6-2.5)⁶
• Cognitive decline and dementia⁷
• Frailty and functional decline in older adults⁸

3. Clinical Interpretation

hs-CRP Level (mg/L)	Cardiovascular Risk Category	Longevity Implications
<1.0	Low risk	Optimal for longevity
1.0-3.0	Moderate risk	Elevated — lifestyle intervention warranted
3.0-10.0	High risk	Significant — investigate underlying causes
>10.0	Very high risk	May indicate acute infection/inflammation — repeat in 2-4 weeks

4. Mechanisms Linking Inflammation to Aging

Elevated CRP is not merely a marker — it may actively contribute to age-related pathology through multiple mechanisms:

• Endothelial dysfunction: CRP upregulates adhesion molecules (ICAM-1, VCAM-1) and reduces nitric oxide bioavailability⁹
• Atherogenesis: CRP promotes macrophage uptake of LDL and foam cell formation
• Insulin resistance: Inflammatory cytokines interfere with insulin signaling via serine phosphorylation of IRS-1¹⁰
• Telomere attrition: Oxidative stress and inflammation accelerate telomere shortening¹¹
• Cellular senescence: SASP factors maintain a pro-inflammatory milieu

5. Evidence-Based Interventions to Lower hs-CRP

5.1 Lifestyle Interventions

Intervention	Effect Size	Evidence Quality
Weight loss (5-10% body weight)	-30 to -50% hs-CRP	Strong (multiple RCTs)
Aerobic exercise (150+ min/week)	-15 to -30%	Strong
Mediterranean diet	-20 to -35%	Strong (PREDIMED)
Smoking cessation	-30 to -50%	Strong
Sleep optimization (7-8 hrs)	-10 to -20%	Moderate
Stress reduction (meditation)	-10 to -25%	Moderate

5.2 Pharmacological Interventions

Colchicine: Low-dose colchicine (0.5 mg/day) reduced cardiovascular events by 31% in the COLCOT trial, with particular benefit in patients with elevated hs-CRP¹³.

Metformin: The TAME Trial (Targeting Aging with Metformin) is investigating whether metformin can delay age-related diseases. Preliminary data suggest modest CRP-lowering effects (~10-15%).

5.3 Nutraceutical Interventions

Compound	Effect Size	Evidence Quality	Notes
Omega-3 fatty acids (EPA/DHA)	-15 to -30%	Strong	Dose-dependent; 2-4 g/day EPA
Curcumin	-20 to -40%	Moderate	Bioavailability is limiting factor
Vitamin D	-10 to -25% (if deficient)	Moderate	Only effective if baseline <30 ng/mL
Fiber (psyllium, inulin)	-10 to -20%	Moderate	Mechanism: gut microbiome modulation
Green tea extract (EGCG)	-10 to -20%	Limited	Most studies in metabolic syndrome

6. Measurement Considerations

• Fasting: Not strictly required, but consistent conditions improve longitudinal tracking
• Timing: Avoid measurement during acute illness, within 2 weeks of intense exercise, or during active infection
• Variability: Intra-individual CV is ~30-40%. Trend over time matters more than single values
• Assay standardization: Different platforms (immunoturbidimetric vs nephelometric) may yield slightly different absolute values

7. Conclusion

hs-CRP is one of the most robust and accessible biomarkers of systemic inflammation and biological aging. Unlike many longevity biomarkers, it is inexpensive, widely available, and has extensive outcome data linking it to cardiovascular events, diabetes, cognitive decline, and mortality.

The strongest evidence for CRP reduction comes from lifestyle interventions — weight loss, exercise, Mediterranean diet, and smoking cessation. These should be the foundation of any longevity protocol. Pharmacological and nutraceutical interventions may provide additional benefit, particularly in high-risk individuals, but should complement rather than replace lifestyle modification.